In light of the recent evidence demonstrating a beneficial systemic immune response and higher overall survival of metastatic breast cancer patients receiving TGFβ blockade during radiotherapy59, TGFβ1 becomes an attractive target with promising prognostic and therapeutic applications in IRI context. Here, TGFB1 is linked to breast carcinoma.